Ruxolitinib Yielded High Response Rate in Children With Refractory GVHD Cancer Therapy Advisor, 12 Mar 2021 Additional or replacement treatment with ruxolitinib for acute or chronic graft-vs-host disease (GVHD) resulted in a high…